<DOC>
	<DOCNO>NCT00373113</DOCNO>
	<brief_summary>To compare efficacy safety Sunitinib Capecitabine subject advance breast cancer fail taxane anthracycline chemotherapy regimen fail taxane anthracycline therapy indicate</brief_summary>
	<brief_title>A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine</brief_title>
	<detailed_description>Patient enrollment trial discontinue base statistical assessment futility . An independent Data Monitoring Committee find even trial allow continue , treatment single agent sunitinib would unable demonstrate statistically significant improvement primary endpoint progression-free survival compare single agent capecitabine study population . Pfizer notify clinical trial investigator involve study regulatory agency find 25Mar2009 . Patients receive sunitinib allow receive capecitabine enter extension trial receive clinical benefit continue sunitinib therapy . There safety concern lead decision terminate study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>breast adenocarcinoma prior treatment anthracycline taxane either concurrently sequentially neoadjuvant , adjuvant or/ advance disease treatment setting . No 1 chemotherapy regimen advance set Prior treatment regimens chemotherapy advanced/metastatic disease set beyond contain anthracyclines taxanes multiple anthracyclines/ taxanes treatment . Any prior regimen capecitabine</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>advanced breast cancer</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>treatment resistant</keyword>
	<keyword>treatment failure</keyword>
</DOC>